Loading...
•
Dec 31, 2022
Pacira Q4 2022 Earnings Report
Pacira BioSciences reported solid financial results with record revenue and significant adjusted EBITDA. EXPAREL surpassed twelve million patients, and the product portfolio advanced into new indications.
Key Takeaways
Pacira BioSciences reported a revenue of $172.0 million for Q4 2022, an 8% increase compared to Q4 2021. The company's GAAP net loss was $10.1 million, or $0.22 per basic and diluted share, while adjusted EBITDA was $58.8 million.
Total revenues were $172.0 million, an 8% increase year-over-year.
EXPAREL net product sales were $138.0 million, a 1% decrease year-over-year.
ZILRETTA net product sales were $28.0 million, a 121% increase year-over-year.
GAAP net loss was $10.1 million, or $0.22 per basic and diluted share.
Revenue by Segment
Forward Guidance
Pacira provided full-year 2023 financial guidance.
Positive Outlook
- EXPAREL net product sales of $570 million to $580 million
- ZILRETTA net product sales of $115 million to $125 million
- iovera° net product sales of $17 million to $20 million
- Non-GAAP Gross margin of 76% to 78%
- Non-GAAP R&D expense of $70 million to $80 million
Challenges Ahead
- Non-GAAP SG&A expense of $220 million to $230 million
- Stock-based compensation of $51 million to $54 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...